Synera (Nuvo Research) significantly improves Pain in Shoulder Impingement Syndrome

New data on Synera (lidocaine and tetracaine) topical patch, from Nuvo Research, showed that Synera provided clinically significant improvement of Pain and function in Shoulder Impingement Syndrome (SIS). The data was a pooled analysis of two open label pilot studies of Synera. 70% of patients experienced a clinically meaningful reduction (more than a 30% reduction) in average pain scores. In addition, improvements were noted by reductions in pain interference with sleep, work, and general activity, as well as, improvements in range of motion in the affected shoulder.

Approximately 76% of patients reported being "satisfied" or "very satisfied" with the treatment. No serious adverse events were reported in either study. Synera is approved in the EU and US for local dermal analgesia but not for SIS. Results were presented by Dr. Richard Radnovich, Injury Care Medical Center, Boise, ID, US at the Annual Meeting of the American Medical Society for Sports Medicine.